United Therapeutics (UTHR) CEO A Sells $5.1M of Stock

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, sold 9,500 shares of the company's stock on October 14, 2026. The shares were sold for about $5.1 million at an average price of $539.99 each. This was a planned transaction, part of Rothblatt's ongoing management of her holdings.

Inside Rothblatt's Trade

Rothblatt's sale of 9,500 shares represents a significant transaction in the context of her overall ownership in United Therapeutics. This sale follows her earlier planned sale of the same number of shares on October 13, 2026, which was also valued at approximately $5.2 million. Her recent trades indicate a strategic adjustment as the company approaches its next earnings report.

Other Institutional Activity in United Therapeutics

Several institutional investors have adjusted their positions in United Therapeutics recently. Blackrock Inc. reduced its stake by 105,297 shares, ending with 5,294,529 shares worth about $2.82 billion. Avoro Capital Advisors LLC added 147,804 shares, growing its holdings to 2,777,777 shares valued at approximately $1.48 billion. Meanwhile, State Street Corporation increased its position by 54,030 shares, totaling 1,898,064 shares worth about $1.01 billion.

United Therapeutics Corporation Stock Up 0.1%

United Therapeutics shares recently traded around $541.98, which is above its 50-day moving average of $514.66 by 5.3%. However, the stock is still 11.1% below its 52-week high of $609.35. With a market cap of about $22.87 billion and a P/E ratio of 19.1, the stock's current position reflects a mix of investor sentiment and market performance.

Recent Earnings

For the trailing twelve months, United Therapeutics reported revenue of approximately $3.15 billion with an EPS of $27.92. The company's net margin stands at 41.6%, and it has a return on equity of 19.3%. The next earnings report is scheduled for October 28, 2026, which could further influence stock performance.

Insider Buying and Selling at United Therapeutics Corporation

In recent insider activity, Martine Rothblatt has been active in trading shares. On June 29, 2026, she bought 9,500 shares for $1.29 million at an average price of $135.42. She then sold 9,500 shares on October 14, 2026, for about $5.1 million. These transactions show a notable pattern of buying and selling, reflecting her strategic management of her holdings.

Analysts Set New Price Targets

On October 8, 2026, RBC Capital maintained its 'Outperform' rating with a price target of $708, up from a previous target of $677. Meanwhile, Goldman Sachs initiated coverage with a 'Sell' rating and a target price of $321. The consensus among analysts remains positive, with a mean target price of $656.93 based on 14 opinions, suggesting a general expectation for the stock's upward potential.

About United Therapeutics

United Therapeutics Corporation focuses on developing and commercializing medical products for patients with chronic and life-threatening diseases. With headquarters in Silver Spring, MD, the company plays a crucial role in addressing unmet medical needs in the healthcare sector. This insider activity occurs as United Therapeutics prepares to release its quarterly financial results, which may impact investor sentiment and stock performance.

Bottom Line

Investors should keep an eye on the upcoming earnings report on October 28, 2026, as it could significantly impact United Therapeutics' stock performance. Additionally, Rothblatt's recent insider trades may provide insights into her confidence in the company's future prospects.